HIF Hydroxylases and Non-Small Cell Lung Cancer Survival
Author Information
Author(s): Andersen Sigve, Donnem Tom, Stenvold Helge, Al-Saad Samer, Al-Shibli Khalid, Busund Lill-Tove, Bremnes Roy M.
Primary Institution: Institute of Clinical Medicine, University of Tromso, Tromso, Norway
Hypothesis
The study aimed to investigate the prognostic impact of HIF hydroxylases in non-small cell lung cancer (NSCLC).
Conclusion
High expression of HIF hydroxylases is associated with poor survival in NSCLC patients.
Supporting Evidence
- High expression of PHD1, PHD2, PHD3, and FIH was associated with poor disease-specific survival.
- Patients with no high expression of HIF hydroxylases had a 5-year survival of 80%, compared to 23% for those with all four highly expressed.
- PHD2 was identified as the most significant independent prognostic factor.
Takeaway
This study found that certain proteins related to oxygen sensing in tumors can predict how well patients with lung cancer will do after treatment.
Methodology
The study used tumor tissue samples from 335 NSCLC patients and evaluated hydroxylase expression through immunohistochemistry.
Potential Biases
Potential bias in patient selection and retrospective data collection.
Limitations
The study is retrospective and may have selection bias due to the exclusion of patients with inadequate tissue samples.
Participant Demographics
Median age was 67 years, 75% were male, and 95% were current or former smokers.
Statistical Information
P-Value
PHD1 (P=0.023), PHD2 (P=0.013), PHD3 (P=0.018), FIH (P=0.033)
Confidence Interval
PHD2 (HR=2.03, CI 95% 1.20–3.42), PHD1 (HR=1.45, CI 95% 1.01–2.10)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website